



Summit Medical transfers ambIT products to Avanos Medical

BTC health (ASX:BTC) has been notified that Summit Medical Products is transferring its ambIT range of products and associated distribution arrangements to Avanos Medical (NYSE: AVNS) in Atlanta, USA.

Pursuant to the asset sale transaction, Summit Medical's rights and obligations under the exclusive distribution contract with BTC Speciality Health Pty Ltd, a wholly owned subsidiary of BTC health, are to be assigned, without amendment, to Avanos Inc. BTC Speciality Health will continue as the exclusive distributor of the ambIT range of products in Australia and New Zealand, with the expiration date of the contract remaining at 31 December 2026.

“Our intent is to continue Summit’s current arrangements with BTC Health in Australia and New Zealand. Any existing contracts in place with Summit prior to the acquisition will remain in full force and effect,” said Warren Machan, Senior VP Avanos Medical.

BTC health Chairman Richard Treagus commented: “We look forward to working closely with Avanos as our Speciality Health hospital sales team continues to educate, promote and grow the ambIT product range in Australia and New Zealand.”

Forward-looking Statements

This ASX-announcement may contain forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of BTC health to be materially different from the statements in this announcement.

About BTC health

BTC health is a listed entity on the ASX and is a Pooled Development Fund, registered under the Pooled Development Funds Act 1992. The company’s strategy is to make active investments in businesses that acquire, develop and commercialize innovative products in the healthcare sector, and which can benefit from greater access to growth capital. The company has the long-term objective of building a group of complementary high-growth businesses which when operating together generate better patient health outcomes and value for its shareholders.

Under the Pooled Development Funds Act 1992, shareholders are entitled to concessionary tax treatment in Australia for income and capital gains derived in connection with their shareholding. Gains realised on the disposal of shares will not be included in an investor’s assessable income in Australia. An investor will not be entitled to any deduction or capital loss on the sale of shares. Unfranked dividends received by an Australian resident will be exempt from tax. Franked dividends will also be exempt from tax unless the shareholder elects to be taxed. An Australian corporate tax entity may credit its franking account (with franking credits attaching to a franked dividend), regardless of whether it has elected to treat the dividend as exempt or assessable income. Dividends paid to non-residents will not be subject to withholding tax. A shareholder or prospective shareholder should obtain their own tax advice rather than relying on this summary.